Abound Bio generates novel human antibodies including antibody domains for more effective therapeutic targeting of infectious diseases and difficult to manage cancers.
Founded by two successful leaders in the therapeutic antibody space, John Mellors, MD, and Dimiter Dimitrov, PhD, ScD, Abound Bio has a unique, proprietary approach to antibody library development, selection and engineering of candidate therapeutics.
A very common form of biologic therapy is an antibody (Ab), a protein produced by the immune system. The Abound Bio team has overcome well-known limitations with antibody’s size and has developed fully human antibody libraries in multiple formats ready for rapid discovery of high affinity binders for therapeutic targeting via multiple approaches.
Abound Bio’s differentiators include:
Novel Antibody Libraries
Abound Bio’s proprietary methodologies to build libraries increases their size, binder diversity, coverage of potential antigens, screening capacity, and probability of identifying a lead therapeutic antibody candidate.
Abound Bio’s breadth of binder format provides a greater chance of success by incorporating its diversified binder sets (Fab, scFv, VH) into the appropriate therapeutic platforms (bi- and multi-specific antibodies, bispecific T-cell and NK-cell engagers, antibody-drug and antibody-radionuclide conjugates, CAR-T and CAR–NK cells). Each indication and target may have different requirements; thus, the breadth of binder formats and therapeutic platforms provides a greater chance for success.
Highly experienced senior executive with 30+ year’s experience in private and public companies, company formation and growth, technology and company investments, pharmaceutical and medical device product development, basic research, clinical development, regulatory affairs, strategic planning, business development, licensing, project management, investor relations and executive management.